01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
The recent decision in Dyer v. Ventra Sandusky, LLC, issued by the U.S. Sixth Circuit Court of Appea...
Read More >
Since the advent of computers there have always been fear of job losses, but new jobs have been crea...
Read More >
California employers just received a last-minute reprieve from complying with a newly enacted law th...
Read More >
Bricker & Eckler attorneys, with special guest Thomas Winston, President & CEO, Toledo-Lucas County ...
Read More >
The Rhode Island Superior Court came down with a few interesting decisions this year concerning Rhod...
Read More >
Relief Obtained for Black Applicant Denied Vending Servicer Job Because of Race - SOUTH BEND, Ind. ...
Read More >